Tags

Type your tag names separated by a space and hit enter

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
J Neural Transm (Vienna). 2004 Aug; 111(8):1053-63.JN

Abstract

The efficacy of entacapone and its impact on patient quality of life (QOL) was investigated in an open-label study of 899 patients with idiopathic Parkinson's Disease (PD) experiencing wearing-off fluctuations. Patients were divided into 3 groups (3, 4 or 5 doses daily) based on their current levodopa dosage frequency. Patients received 200 mg entacapone with each levodopa/dopa-decarboxylase inhibitor (DDCI) dose, while continuing their same levodopa/DDCI dosage regimen for 4 weeks. Primary efficacy measure was the Investigators' Clinical Global Impression of Change (CGIC). Patient QoL was assessed using the validated 8-item Parkinson's Disease Questionnaire (PDQ-8). Investigators' CGIC revealed that 76.5% of entacapone treated patients experienced an improvement in global status after 4 weeks. Treatment with entacapone was also associated with improvement in patient QoL, with a mean reduction (improvement) in PDQ-8 score of 1.8 from baseline. This study confirms and extends the results of earlier studies demonstrating that, independent of dosing frequency, completing levodopa/DDCI therapy with entacapone provides clinically relevant improvements in global status and QoL in PD patients experiencing wearing-off on their current levodopa dosing frequency.

Authors+Show Affiliations

Servizio di Neurofisiopatologia, Pescara, Italy. onofrj@unich.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

15254793

Citation

Onofrj, M, et al. "Combining Entacapone With levodopa/DDCI Improves Clinical Status and Quality of Life in Parkinson's Disease (PD) Patients Experiencing Wearing-off, Regardless of the Dosing Frequency: Results of a Large Multicentre Open-label Study." Journal of Neural Transmission (Vienna, Austria : 1996), vol. 111, no. 8, 2004, pp. 1053-63.
Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm (Vienna). 2004;111(8):1053-63.
Onofrj, M., Thomas, A., Vingerhoets, F., Martin, W., Giménez-Roldán, S., Azulay, J. P., Bernhard, G., Schmidt, W., & Markabi, S. (2004). Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. Journal of Neural Transmission (Vienna, Austria : 1996), 111(8), 1053-63.
Onofrj M, et al. Combining Entacapone With levodopa/DDCI Improves Clinical Status and Quality of Life in Parkinson's Disease (PD) Patients Experiencing Wearing-off, Regardless of the Dosing Frequency: Results of a Large Multicentre Open-label Study. J Neural Transm (Vienna). 2004;111(8):1053-63. PubMed PMID: 15254793.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. AU - Onofrj,M, AU - Thomas,A, AU - Vingerhoets,F, AU - Martin,W, AU - Giménez-Roldán,S, AU - Azulay,J-P, AU - Bernhard,G, AU - Schmidt,W, AU - Markabi,S, Y1 - 2004/05/12/ PY - 2003/08/26/received PY - 2004/03/19/accepted PY - 2004/7/16/pubmed PY - 2004/12/16/medline PY - 2004/7/16/entrez SP - 1053 EP - 63 JF - Journal of neural transmission (Vienna, Austria : 1996) JO - J Neural Transm (Vienna) VL - 111 IS - 8 N2 - The efficacy of entacapone and its impact on patient quality of life (QOL) was investigated in an open-label study of 899 patients with idiopathic Parkinson's Disease (PD) experiencing wearing-off fluctuations. Patients were divided into 3 groups (3, 4 or 5 doses daily) based on their current levodopa dosage frequency. Patients received 200 mg entacapone with each levodopa/dopa-decarboxylase inhibitor (DDCI) dose, while continuing their same levodopa/DDCI dosage regimen for 4 weeks. Primary efficacy measure was the Investigators' Clinical Global Impression of Change (CGIC). Patient QoL was assessed using the validated 8-item Parkinson's Disease Questionnaire (PDQ-8). Investigators' CGIC revealed that 76.5% of entacapone treated patients experienced an improvement in global status after 4 weeks. Treatment with entacapone was also associated with improvement in patient QoL, with a mean reduction (improvement) in PDQ-8 score of 1.8 from baseline. This study confirms and extends the results of earlier studies demonstrating that, independent of dosing frequency, completing levodopa/DDCI therapy with entacapone provides clinically relevant improvements in global status and QoL in PD patients experiencing wearing-off on their current levodopa dosing frequency. SN - 0300-9564 UR - https://www.unboundmedicine.com/medline/citation/15254793/Combining_entacapone_with_levodopa/DDCI_improves_clinical_status_and_quality_of_life_in_Parkinson's_Disease__PD__patients_experiencing_wearing_off_regardless_of_the_dosing_frequency:_results_of_a_large_multicentre_open_label_study_ L2 - https://doi.org/10.1007/s00702-004-0149-4 DB - PRIME DP - Unbound Medicine ER -